Asuragen, Inc. Launches SuraSeq Next Generation Sequencing Panel in Its CAP Accredited CLIA Laboratory
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc., a leading molecular diagnostic company, announced today the launch of its SuraSeq™ Next Generation Sequencing (NGS) Service in its CAP accredited CLIA Laboratory. The SuraSeq™ 500 Clinical Cancer Panel was designed in response to guidelines from the National Comprehensive Cancer Network (NCCN) and will be the first of several targeted oncology panels to be offered in its clinical laboratory. The SuraSeq™ 500 Clinical Panel interrogates 17 key cancer pathway genes and more than 500 annotated COSMIC mutations.
Help employers find you! Check out all the jobs and post your resume.
AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc., a leading molecular diagnostic company, announced today the launch of its SuraSeq™ Next Generation Sequencing (NGS) Service in its CAP accredited CLIA Laboratory. The SuraSeq™ 500 Clinical Cancer Panel was designed in response to guidelines from the National Comprehensive Cancer Network (NCCN) and will be the first of several targeted oncology panels to be offered in its clinical laboratory. The SuraSeq™ 500 Clinical Panel interrogates 17 key cancer pathway genes and more than 500 annotated COSMIC mutations.
Help employers find you! Check out all the jobs and post your resume.